Literature DB >> 24838325

VE1 antibody immunoreactivity in normal anterior pituitary and adrenal cortex without detectable BRAF V600E mutations.

Daniel A Mordes1, Kerry Lynch1, Sharon Campbell1, Dora Dias-Santagata1, Vania Nose1, David N Louis1, Mai P Hoang2.   

Abstract

OBJECTIVES: The VE1 monoclonal antibody was developed to recognize the V600E mutation in BRAF, which is found in various tumors.
METHODS: We report that the VE1 antibody stains normal anterior pituitary gland and adrenal cortex, which lack detectable BRAF V600E mutations.
RESULTS: Staining with the VE1 antibody was seen in the adenohypophysis and correlated well with adrenocorticotropic hormone (ACTH)-positive cells. ACTH-positive cells were typically most concentrated in the central mucoid wedge and pars intermedia, and VE1 staining was strong in these regions. Moreover, VE1 staining was seen in ACTH-expressing pituitary adenomas without detectable BRAF mutations. VE1 staining of the adrenal cortex was also significant, with the strongest staining seen in the inner segment of the zona fasciculata. Parathyroid glands, pancreatic islets, or parafollicular C cells in the thyroid showed no VE1 staining.
CONCLUSIONS: Overall, VE1 staining of endocrine tissues strongly suggests limitations on the use of this antibody for the detection of BRAF mutations. Copyright© by the American Society for Clinical Pathology.

Entities:  

Keywords:  Adrenal gland; BRAF V600E; Immunohistochemistry; Pituitary gland; VE1

Mesh:

Substances:

Year:  2014        PMID: 24838325     DOI: 10.1309/AJCP37TLZLTUAOJL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.

Authors:  Bette K Kleinschmidt-DeMasters; Dara L Aisner; Nicholas K Foreman
Journal:  Am J Surg Pathol       Date:  2015-04       Impact factor: 6.394

2.  Cross-reactivity of the BRAF VE1 antibody with epitopes in axonemal dyneins leads to staining of cilia.

Authors:  Robert T Jones; Malak S Abedalthagafi; Mohan Brahmandam; Edward A Greenfield; Mai P Hoang; David N Louis; Jason L Hornick; Sandro Santagata
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

3.  Immunohistochemical Expression of p16 and p21 in Pituitary Tissue Adjacent to Pituitary Adenoma versus Pituitary Tissue Obtained at Autopsy: Is There a Difference?

Authors:  Emilija Manojlovic Gacic; Milica Skender-Gazibara; Ivan Soldatovic; Dusko Dundjerovic; Novica Boricic; Savo Raicevic; Vera Popovic
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

Review 4.  ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.

Authors:  Priscilla K Brastianos; Sandro Santagata
Journal:  Eur J Endocrinol       Date:  2015-11-12       Impact factor: 6.664

Review 5.  BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.

Authors:  Jung-Soo Pyo; Jin Hee Sohn; Guhyun Kang
Journal:  Endocr Pathol       Date:  2015-09       Impact factor: 3.943

6.  Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.

Authors:  Felix Behling; Alonso Barrantes-Freer; Marco Skardelly; Maike Nieser; Arne Christians; Florian Stockhammer; Veit Rohde; Marcos Tatagiba; Christian Hartmann; Christine Stadelmann; Jens Schittenhelm
Journal:  Diagn Pathol       Date:  2016-06-27       Impact factor: 2.644

Review 7.  Recent advances in molecular pathology of craniopharyngioma.

Authors:  Sarah Larkin; Niki Karavitaki
Journal:  F1000Res       Date:  2017-07-24

8.  Clinical Relevance of BRAF V600E Mutation Status in Brain Tumors with a Focus on a Novel Management Algorithm.

Authors:  Adam Kowalewski; Justyna Durślewicz; Marek Zdrenka; Dariusz Grzanka; Łukasz Szylberg
Journal:  Target Oncol       Date:  2020-08       Impact factor: 4.493

Review 9.  Histopathology of Parasellar Neoplasms.

Authors:  Emilija Manojlovic-Gacic; Elham Rostami; Niki Karavitaki; Olivera Casar-Borota
Journal:  Neuroendocrinology       Date:  2020-03-11       Impact factor: 4.914

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.